Mechanism of Toxic Action of MPTP in the Brain

Abstract

Get full access to this article

View all access options for this article.

References

Ballard PA , Tetrud JW & Langston JW Permanent human parkinsonism due to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): Seven cases. Neurology 1985; 35: 949-56.

Burns RS , Chiueh CC , Markey SP , Ebert MH , Jacobowitz DM & Kopin IJ A primate model of parkinsonism: selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine . Proceedings of National Academy of Science USA 1983 ; 80: 4546-50.

Langston JW & Irwin I. MPTP: current concepts and controversies. Clinical Neuropharmacology 1986; 9: 485-507.

Singer TP , Castagnoli N. Jr, Ramsay RR & Trevor AJ Biochemical events in the development of parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine . Journal of Neurochemistry 1987; 49: 1-8.

Nicklas WJ , Vyas I. & Heikkila RE Inhibition of NADH-linked oxidation in brain mitochondria by 1-methyl-4-phenylpyridine, a metabolite of the neurotoxin, 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine . Life Sciences 1985; 36: 2503-8.

Forno LS , Langston JW , DeLanney LE , Irwin I. & Ricaurte GA Locus ceruleus lesions and eosinophilic inclusions in MPTP-treated monkeys . Annals of Neurology 1986; 20: 449-55.

Kindt MV , Youngster SK , Sonsalla PK , Duvoisin RC & Heikkila RE Role for monoamine oxidase-A (MAO-A) in the bioactivation and nigrostriatal dopaminergic neurotoxicity of the MPTP analog, 2'Me-MPTP. European Journal of Pharmacology 1988; 146: 313-8.